Differentiation Makes a Difference In Biopharma Partnering Success
BOSTON A common refrain heard last week at BioPharm America 2012 in Boston was the need for biotechs to consider partnering opportunities at every step along the path to commercialization, from preclinical to post-approval. The optimum success strategy? In a word: Differentiate.
Epizyme Inc. banked $135 million in up-front and milestone payments from three partnerships before it moved lead compound EPZ-5676, a small-molecule inhibitor of histone methyltransferase (HMT) DOT1L, into a Phase I study earlier this month.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter